NCT00538733 · OUTCOME

Event Free Survival

Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma · Source last updated 2021-05-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: from baseline to the time of first event that lead to removal from study (defined as progression, death, withdrawal of consent, or removal for toxicity)

Groups in this outcome

T-BiRD Therapy (All Patients)

All 26 patients that were enrolled onto the study were assessed for event free survival.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
T-BiRD Therapy (All Patients)	26

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
T-BiRD Therapy (All Patients)	21.5	Not reported	4.2	57.4	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
4.2
upper Limit
57.4
value
21.5

denoms

counts
group Id
OG000
value
26
units
Participants

dispersion Type

95% Confidence Interval

groups

description
All 26 patients that were enrolled onto the study were assessed for event free survival.
id
OG000
title
T-BiRD Therapy (All Patients)

param Type

MEDIAN

reporting Status

POSTED

time Frame

from baseline to the time of first event that lead to removal from study (defined as progression, death, withdrawal of consent, or removal for toxicity)

title

Event Free Survival

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice